The human eye comprises several layers. The white outer layer is the sclera, which surrounds the choroid layer. The retina is interior to the choroid layer. The sclera contains collagen and elastic fiber, providing protection to the choroid and retina. The choroid layer includes vasculature providing oxygen and nourishment to the retina. The retina comprises light sensitive tissue, including rods and cones. In some instances, it may be desirable to inject a fluid into the suprachroidal space, between the choroid layer and the sclera. By way of example only, such an injected fluid may include a drug, a viscoelastic to treat retinal detachment, and/or various other kinds of substances to address various kinds of conditions.
Some procedures to inject a fluid into the suprachoroidal space may include the use of a transscleral external needle with a depth control feature that provides a fixed exposed distance of needle penetration into the sclera. This approach may not provide sufficient precision to accommodate variations in patient anatomy, since sclera thickness may vary from patient to patient. In patients with a relatively thin sclera, the needle may penetrate the choroid, and in some cases even penetrate the retina, which may produce an undesirable result. In patients with a relatively thick sclera, the needle may fail to reach the suprachoroidal space, which may render the treatment completely ineffective.
Some other procedures to inject a fluid into the suprachoroidal space may include the use of a rigid steel cannula to enter the suprachoroidal space through a sclerotomy. This approach may be relatively technique sensitive with respect to the angle and depth of entry, such that it may be undesirably too easy to inadvertently penetrate the choroid and retina with the rigid steel cannula.
It may therefore be desirable to provide a device that enables the delivery of fluid into the suprachoroidal space with substantial precision and without substantial risk of inadvertent penetration of the choroid and retina.
While a variety of devices and methods have been made and used to treat an eye, it is believed that no one prior to the inventors has made or used the invention described in the appended claims.
While the specification concludes with claims which particularly point out and distinctly claim this technology, it is believed this technology will be better understood from the following description of certain examples taken in conjunction with the accompanying drawings, in which like reference numerals identify the same elements and in which:
The drawings are not intended to be limiting in any way, and it is contemplated that various embodiments of the technology may be carried out in a variety of other ways, including those not necessarily depicted in the drawings. The accompanying drawings incorporated in and forming a part of the specification illustrate several aspects of the present technology, and together with the description serve to explain the principles of the technology; it being understood, however, that this technology is not limited to the precise arrangements shown.
The following description of certain examples of the technology should not be used to limit its scope. Other examples, features, aspects, embodiments, and advantages of the technology will become apparent to those skilled in the art from the following description, which is by way of illustration, one of the best modes contemplated for carrying out the technology. As will be realized, the technology described herein is capable of other different and obvious aspects, all without departing from the technology. Accordingly, the drawings and descriptions should be regarded as illustrative in nature and not restrictive.
It is further understood that any one or more of the teachings, expressions, embodiments, examples, etc. described herein may be combined with any one or more of the other teachings, expressions, embodiments, examples, etc. that are described herein. The following-described teachings, expressions, embodiments, examples, etc. should therefore not be viewed in isolation relative to each other. Various suitable ways in which the teachings herein may be combined will be readily apparent to those of ordinary skill in the art in view of the teachings herein. Such modifications and variations are intended to be included within the scope of the claims.
For clarity of disclosure, the terms “proximal” and “distal” are defined herein relative to a surgeon or other operator grasping a surgical instrument having a distal surgical end effector. The term “proximal” refers the position of an element closer to the surgeon or other operator and the term “distal” refers to the position of an element closer to the surgical end effector of the surgical instrument and further away from the surgeon or other operator.
While syringe (50) is used to provide manual operation of fluid delivery in the present example, some other versions may provide automated fluid delivery. By way of example only, fluid delivery may be automated in accordance with at least some of the teachings of U.S. Pub. No. 2017/0360606, entitled “Injection Device for Subretinal Delivery of Therapeutic Agent,” published Dec. 21, 2017, the disclosure of which is incorporated by reference herein. As another merely illustrative example, a fluid source may be integrated into body (20), with manual or automated delivery being provided via one or more components that are also integral with body (20). Other various ways in which fluid delivery may be automated or provided manually will be apparent to those of ordinary skill in the art in view of the teachings herein.
As shown in
By way of example only, cannula (30) may be formed of a flexible material such as Polyether block amide (PEBA), which may be manufactured under the trade name PEBAX. Of course, any other suitable material or combination of materials may be used. Also in the present example, cannula (30) has a cross-sectional profile dimension of approximately 2.0 mm by 0.8 mm, with a length of approximately 80 mm. Alternatively, any other suitable dimensions may be used. Cannula (30) of the present example is flexible enough to conform to specific structures and contours of the patient's eye, yet cannula (30) has sufficient column strength to permit advancement of cannula (30) between the sclera and choroid of patient's eye without buckling. By way of example only, cannula (30) may be configured and operable in accordance with at least some of the teachings of U.S. Pub. No. 2015/0223977, entitled “Method and Apparatus for Subretinal Administration of Therapeutic Agent,” published Aug. 13, 2015, the disclosure of which is incorporated by reference herein. Also in some versions, cannula (30) includes a flexible polymer tube (not shown) disposed in lumen (38). Such an internal tube may provide additional column strength and/or other properties to cannula (30).
After speculum (80) and fixture (90) are appropriately positioned, the sclera (102) may be accessed by dissecting the conjunctiva by incising a flap in the conjunctiva and pulling the flap posteriorly. After such a dissection is completed, the exposed surface of the sclera (102) may optionally be blanched using a cautery tool to minimize bleeding. Once conjunctiva dissection is complete, the exposed surface of the sclera (102) may optionally be dried using a WECK-CEL or other suitable absorbent device. A template may then be used to mark the eye (100), as described in U.S. Pub. No. 2015/0223977, entitled “Method and Apparatus for Subretinal Administration of Therapeutic Agent,” published Aug. 13, 2015, the disclosure of which is incorporated by reference herein; and/or as described in U.S. Pub. No. 2017/0360605, entitled “Guide Apparatus for Tangential Entry into Suprachoroidal Space,” published Dec. 21, 2017, the disclosure of which is incorporated by reference herein.
An operator may then use a visual guide created using the template to attach a suture loop assembly (120), as shown in
In addition to creating suture loop assembly (120), the operator in the present example also uses a visual guide created using the template to perform a sclerotomy, as shown in
With the sclerotomy procedure performed, the operator then inserts cannula (30) of instrument (10) through incision (130) and into the space between the sclera (102) and the choroid (104). As can be seen in
As cannula (30) traverses the space between the choroid (104) and the sclera (102), traveling from the incision (130) to the point where distal end (34) is shown in
Although not shown, in some examples cannula (30) may include one or more markers on the surface of cannula (30) to indicate various depths of insertion. While merely optional, such markers may be desirable to aid an operator in identifying the proper depth of insertion as cannula (30) is guided along an atraumatic path. For instance, the operator may visually observe the position of such markers in relation to suture loop assembly (120) and/or in relation to the incision (130) in the sclera (102) as an indication of the depth to which cannula (30) is inserted in the eye (100). By way of example only, one such marker may correspond to an approximately 6 mm depth of insertion of cannula (30). Those of ordinary skill in the art will recognize that cannula (30) may be inserted into the eye (100) under direct visualization, such that fiber optics or other special illumination are not necessarily required.
As shown in
In the present example, the delivery site corresponds to a generally posterior region of the eye (100). Of course, the appropriate position of a delivery site may vary, such that in various procedures the appropriate delivery site may be anterior or posterior to the delivery site shown in
Once fluid (140) is delivered to the suprachoroidal space, the operator may withdraw cannula (30) from the eye (100). Suture loop assembly (120) is then removed, and the incision (130) in the sclera (102) is closed using any suitable conventional technique. While
Those of ordinary skill in the art will recognize that the above-described procedure, and the structural configuration of cannula (30), may provide substantial precision to delivery of fluid (140) to the suprachoroidal space. In addition, the above-described procedure, and the structural configuration of cannula (30), may substantially reduce the risk of inadvertent penetration of the choroid (104) and retina (106) (as compared to conventional techniques/instruments for delivering fluid to the suprachoroidal space). The above-described procedure and system (10) may thus ultimately provide a relatively short learning curve for operators seeking to deliver fluid (140) to the suprachoroidal space of an eye (100) of a patient.
By way of example only, the above-described procedure and system (10) may be used to deliver fluid (140) to the suprachoroidal space of an eye (100) of a patient having retinal detachment, age related macular degeneration, diabetic macular edema, inherited retinal diseases, retinitis pigmentosa, retinal vein occlusion, diabetic retinopathy, posterior uveitis, Stargardt disease, etc. Other suitable scenarios in which it may be desirable to deliver fluid (140) to the suprachoroidal space of an eye (100) of a patient will be apparent to those of ordinary skill in the art in view of the teachings herein.
The following examples relate to various non-exhaustive ways in which the teachings herein may be combined or applied. It should be understood that the following examples are not intended to restrict the coverage of any claims that may be presented at any time in this application or in subsequent filings of this application. No disclaimer is intended. The following examples are being provided for nothing more than merely illustrative purposes. It is contemplated that the various teachings herein may be arranged and applied in numerous other ways. It is also contemplated that some variations may omit certain features referred to in the below examples. Therefore, none of the aspects or features referred to below should be deemed critical unless otherwise explicitly indicated as such at a later date by the inventors or by a successor in interest to the inventors. If any claims are presented in this application or in subsequent filings related to this application that include additional features beyond those referred to below, those additional features shall not be presumed to have been added for any reason relating to patentability.
An apparatus, comprising: (a) a body; (b) a cannula extending distally from the body, wherein the cannula is flexible, wherein the cannula has a distal end, wherein the cannula defines a lumen distally terminating at the distal end, wherein the cannula is sized and configured to pass between a sclera layer and a choroid layer in a human eye; (c) a conduit in fluid communication with the lumen; and (d) a magnetic element positioned in the body.
The apparatus of Example 1, wherein the distal end of the cannula is rounded.
The apparatus of any one or more of Examples 1 through 2, wherein the cannula has a pair of opposing flat sides and a pair of opposing rounded sides, wherein the flat sides and the rounded sides together define a cross-sectional perimeter of the cannula.
The apparatus of any one or more of Examples 1 through 3, further comprising a fluid source coupled with the conduit, wherein the lumen and the conduit are operable to communicate fluid from the fluid source.
The apparatus of Example 4, wherein the fluid source comprises a syringe.
The apparatus of any one or more of Examples 4 through 5, wherein the fluid source is spaced away from the body via the conduit.
The apparatus of any one or more of Examples 1 through 6, wherein the conduit comprises a flexible tube.
The apparatus of any one or more of Examples 1 through 7, wherein the cannula defines a longitudinal axis, wherein the distal end has an opening positioned on the longitudinal axis, wherein the opening is in fluid communication with the lumen.
A method of delivering fluid to an eye of a patient, the method comprising: (a) inserting a flexible cannula between a sclera layer and a choroid layer of the eye of the patient, wherein the cannula has an atraumatic distal end defining a distal opening; and (b) dispensing a fluid into a space between the sclera layer and the choroid layer of the eye of the patient via the distal opening of the cannula.
The method of Example 9, further comprising forming an incision in the sclera layer, wherein the act of inserting comprises inserting the flexible cannula through the incision.
The method of any one or more of Examples 9 through 10, further comprising securing a guide to the eye of the patient, wherein the act of inserting comprises passing the flexible cannula through a portion of the guide.
The method of Example 11, wherein the guide comprises a suture loop assembly.
The method of any one or more of Examples 9 through 12, wherein the flexible cannula extends distally from an instrument body, wherein the method further comprises securing the instrument body to the patient.
The method of Example 13, wherein the body includes a magnetic element, the method further comprising securing a magnetic pad to the patient, wherein the act of securing the instrument body comprises engaging the magnetic element with the magnetic pad.
The method of any one or more of Examples 9 through 14, wherein the act of dispensing the fluid comprises actuating a syringe, wherein the syringe is in fluid communication with the distal opening of the cannula.
The method of any one or more of Examples 9 through 15, wherein the act of inserting comprises positioning the distal end to a posterior region of the eye of the patient, wherein the act of dispensing comprises dispensing the fluid into the space between the sclera layer and the choroid layer in the posterior region of the eye of the patient.
The method of any one or more of Examples 9 through 16, wherein the cannula separates a portion of the choroid layer from an adjacent portion of the sclera layer during the act of inserting.
The method of any one or more of Examples 9 through 17, wherein the cannula confirms to a curvature of an inner surface of the choroid layer during the act of inserting.
A method of delivering fluid to an eye of a patient, the method comprising: (a) securing a body of an instrument relative to a patient, wherein the instrument includes a flexible cannula extending distally from the body, wherein the flexible cannula has an atraumatic open distal end; (b) forming an incision in the sclera layer of an eye of the patient; (c) inserting the flexible cannula through the incision, thereby positioning distal end of the cannula in a space between the sclera layer and the choroid layer of the eye of the patient, wherein the flexible cannula conforms to a curvature defined by the sclera layer during the act of inserting; and (d) delivering a fluid via the open distal end of the cannula into the space between the sclera layer and the choroid layer of the eye of the patient.
The method of Example 19, further comprising securing a magnetic pad relative to the patient, wherein the body of the instrument includes a magnetic element, wherein the act of securing the body of the instrument relative to a patient comprises achieving a magnetic coupling between the magnetic element and the magnetic pad.
It should be understood that any of the versions of the instruments described herein may include various other features in addition to or in lieu of those described above. By way of example only, any of the devices herein may also include one or more of the various features disclosed in any of the various references that are incorporated by reference herein.
It should be understood that any one or more of the teachings, expressions, embodiments, examples, etc. described herein may be combined with any one or more of the other teachings, expressions, embodiments, examples, etc. that are described herein. The above-described teachings, expressions, embodiments, examples, etc. should therefore not be viewed in isolation relative to each other. Various suitable ways in which the teachings herein may be combined will be readily apparent to those of ordinary skill in the art in view of the teachings herein. Such modifications and variations are intended to be included within the scope of the claims.
It should be appreciated that any patent, publication, or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated material does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.
Versions described above may be designed to be disposed of after a single use, or they can be designed to be used multiple times. Versions may, in either or both cases, be reconditioned for reuse after at least one use. Reconditioning may include any combination of the steps of disassembly of the device, followed by cleaning or replacement of particular pieces, and subsequent reassembly. In particular, some versions of the device may be disassembled, and any number of the particular pieces or parts of the device may be selectively replaced or removed in any combination. Upon cleaning and/or replacement of particular parts, some versions of the device may be reassembled for subsequent use either at a reconditioning facility, or by an operator immediately prior to a procedure. Those skilled in the art will appreciate that reconditioning of a device may utilize a variety of techniques for disassembly, cleaning/replacement, and reassembly. Use of such techniques, and the resulting reconditioned device, are all within the scope of the present application.
By way of example only, versions described herein may be sterilized before and/or after a procedure. In one sterilization technique, the device is placed in a closed and sealed container, such as a plastic or TYVEK bag. The container and device may then be placed in a field of radiation that can penetrate the container, such as gamma radiation, x-rays, or high-energy electrons. The radiation may kill bacteria on the device and in the container. The sterilized device may then be stored in the sterile container for later use. A device may also be sterilized using any other technique known in the art, including but not limited to beta or gamma radiation, ethylene oxide, or steam.
Having shown and described various embodiments of the present invention, further adaptations of the methods and systems described herein may be accomplished by appropriate modifications by one of ordinary skill in the art without departing from the scope of the present invention. Several of such potential modifications have been mentioned, and others will be apparent to those skilled in the art. For instance, the examples, embodiments, geometrics, materials, dimensions, ratios, steps, and the like discussed above are illustrative and are not required. Accordingly, the scope of the present invention should be considered in terms of the following claims and is understood not to be limited to the details of structure and operation shown and described in the specification and drawings.
This application claims priority to U.S. Provisional Patent App. No. 62/445,866, entitled “Suprachoroidal Injection Device,” filed Jan. 13, 2017, the disclosure of which is incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3738359 | Lindquist | Jun 1973 | A |
5409457 | del Cerro et al. | Apr 1995 | A |
5860986 | Reich et al. | Jan 1999 | A |
5964740 | Ouchi | Oct 1999 | A |
6143004 | Davis et al. | Nov 2000 | A |
6162197 | Mohammad | Dec 2000 | A |
6190353 | Makower et al. | Feb 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6299603 | Hecker et al. | Oct 2001 | B1 |
6368315 | Gillis et al. | Apr 2002 | B1 |
6413245 | Yaacobi et al. | Jul 2002 | B1 |
6761724 | Zrenner et al. | Jul 2004 | B1 |
6824532 | Gillis et al. | Nov 2004 | B2 |
7189245 | Kaplan | Mar 2007 | B2 |
7207980 | Christian et al. | Apr 2007 | B2 |
7381404 | Schwartz et al. | Jun 2008 | B2 |
7413734 | Mistry et al. | Aug 2008 | B2 |
7914803 | Chowhan et al. | Mar 2011 | B2 |
7918814 | Prausnitz et al. | Apr 2011 | B2 |
8172830 | Christian et al. | May 2012 | B2 |
8197435 | Prausnitz et al. | Jun 2012 | B2 |
8298521 | Schwartz et al. | Oct 2012 | B2 |
8425473 | Ho et al. | Apr 2013 | B2 |
8569272 | Lyons et al. | Oct 2013 | B2 |
8636713 | Prausnitz | Jan 2014 | B2 |
8808225 | Prausnitz et al. | Aug 2014 | B2 |
9314425 | Whitcup | Apr 2016 | B2 |
9486357 | Peyman | Nov 2016 | B2 |
9788995 | Prausnitz et al. | Oct 2017 | B2 |
9956114 | Andino et al. | May 2018 | B2 |
10076526 | Shiah et al. | Sep 2018 | B2 |
20020133184 | LoRusso | Sep 2002 | A1 |
20020143302 | Hinchliffe et al. | Oct 2002 | A1 |
20040039253 | Peyman et al. | Feb 2004 | A1 |
20040138562 | Makower et al. | Jul 2004 | A1 |
20040199130 | Chornenky | Oct 2004 | A1 |
20050143363 | de Juan et al. | Jun 2005 | A1 |
20050266047 | Tu et al. | Dec 2005 | A1 |
20060025720 | Sawa et al. | Feb 2006 | A1 |
20060047250 | Hickingbotham et al. | Mar 2006 | A1 |
20060293647 | McRae et al. | Dec 2006 | A1 |
20070202186 | Yamamoto et al. | Aug 2007 | A1 |
20080004596 | Yun et al. | Jan 2008 | A1 |
20080058704 | Hee et al. | Mar 2008 | A1 |
20080161845 | Murakami et al. | Jul 2008 | A1 |
20080281292 | Hickingbotham et al. | Nov 2008 | A1 |
20100004499 | Brigatti et al. | Jan 2010 | A1 |
20100042118 | Garrison et al. | Feb 2010 | A1 |
20100173866 | Hee et al. | Jul 2010 | A1 |
20100305514 | Valenti et al. | Dec 2010 | A1 |
20110207987 | DiCarlo et al. | Aug 2011 | A1 |
20120071832 | Bunch | Mar 2012 | A1 |
20120191064 | Conston | Jul 2012 | A1 |
20120271272 | Hammack | Oct 2012 | A1 |
20120323220 | Mackay, II et al. | Dec 2012 | A1 |
20130103026 | Kleshinski et al. | Apr 2013 | A1 |
20130211379 | Clair et al. | Aug 2013 | A1 |
20130216623 | Yamamoto et al. | Aug 2013 | A1 |
20130245600 | Yamamoto et al. | Sep 2013 | A1 |
20140121641 | Fischell et al. | May 2014 | A1 |
20150209180 | Prausnitz et al. | Jul 2015 | A1 |
20150223977 | Oberkircher | Aug 2015 | A1 |
20150258120 | Zarnitsyn | Sep 2015 | A1 |
20150351958 | Contiliano et al. | Dec 2015 | A1 |
20150351959 | Clem et al. | Dec 2015 | A1 |
20160074211 | Ko et al. | Mar 2016 | A1 |
20160074212 | Price et al. | Mar 2016 | A1 |
20160074217 | Price et al. | Mar 2016 | A1 |
20160081849 | Tsai et al. | Mar 2016 | A1 |
20160106587 | Jarrett | Apr 2016 | A1 |
20160143776 | Rotenstreich | May 2016 | A1 |
20160228359 | Whitcup | Aug 2016 | A1 |
20170095369 | Andino et al. | Apr 2017 | A1 |
20170290702 | Yamamoto et al. | Oct 2017 | A1 |
20170333416 | Zarnitsyn et al. | Nov 2017 | A1 |
20170340560 | Yamamoto et al. | Nov 2017 | A1 |
20170360605 | Oberkircher et al. | Dec 2017 | A1 |
20170360606 | Price et al. | Dec 2017 | A1 |
20180028356 | Murata | Feb 2018 | A1 |
20180028357 | Prausnitz et al. | Feb 2018 | A1 |
20180042765 | Noronha et al. | Feb 2018 | A1 |
20180042767 | Andino et al. | Feb 2018 | A1 |
Number | Date | Country |
---|---|---|
103327939 | Sep 2013 | CN |
WO 2015187629 | Dec 2015 | WO |
WO 2017042584 | Mar 2017 | WO |
Entry |
---|
Kang, Se Woong, et al. “A new instrument for drainage or injection of fluid within subretinal space.” Retina 23.5 (2003): 661-666. |
Komáromy, András M., et al. “Application of a new subretinal injection device in the dog.” Cell transplantation 15.6 (2006): 511-519. |
Olsen, Timothy W., et al. “Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment.” American journal of ophthalmology 142.5 (2006): 777-787. |
Patel, S. R., et al. “Intraocular Pharmacokinetics of Suprachoroidal Drug Delivery Administered Using Hollow Microneedles.” Investigative Ophthalmology & Visual Science 51.13 (2010): 3796-3796. |
Patel, S., et al. “Suprachoroidal Drug Delivery Using Microneedles.” Investigative Ophthalmology & Visual Science 49.13 (2008): 5006-5006. |
Patel, Samirkumar R., et al. “Suprachoroidal drug delivery to the back of the eye using hollow microneedles.” Pharmaceutical research 28.1 (2011): 166-176. |
Peden, M. C., et al. “Safety Study of Ab-Externo AAV Gene Therapy Delivery to the Subretinal and Suprachoroidal Space Using a 250 Micron Flexible Microcatheter.” Investigative Ophthalmology & Visual Science 50.13 (2009): 1450-1450. |
Schanze, Thomas, et al. “Implantation and testing of subretinal film electrodes in domestic pigs.” Experimental eye research 82.2 (2006): 332-340. |
Soni, M. H., and A. K. Tyagi. “Induction of Choroidal Detachment: A New Surgical Technique for Choroidal Biopsy.” Investigative Ophthalmology & Visual Science 46.13 (2005): 5438-5438. |
Gallab, Mahmoud, et al. “Development of a spherical model with a 3D microchannel: An application to glaucoma surgery.” Micromachines 10.5 (2019): 297. |
Chinese Office Action dated Jun. 5, 2018 for Application No. 201580008275.2, 8 pages. |
Chinese Office Action dated Feb. 14, 2019 for Application No. 201580008275.2, 6 pages. |
European Communication dated Mar. 7, 2019 for Application No. 15708368.4, 6 pages. |
European Communication dated May 19, 2020 for Application No. 15708368.4, 4 pages. |
Extended European Search Report dated Mar. 3, 2021, for Application No. 20200019.6, 9 pages. |
International Search Report and Written Opinion dated Aug. 27, 2015, for International Application No. PCT/US2015/015362, 14 pages. |
International Search Report and Written Opinion dated Jun. 7, 2017 for International Application No. PCT/US2017/021508, 12 pages. |
International Preliminary Report on Patentability dated Sep. 11, 2018 for International Application No. PCT/US2017/021508, 8 pages. |
Japanese Office Action dated Nov. 7, 2018 for Application No. 2016-552291, 3 pages. |
Japanese Office Action dated Aug. 11, 2020 for Application No. 2019-111845, 6 pages. |
U.S. Appl. No. 61/938,956, filed Feb. 12, 2014. |
U.S. Appl. No. 62/049,056, filed Sep. 11, 2014. |
U.S. Appl. No. 62/049,089, filed Sep. 11, 2014. |
U.S. Appl. No. 62/049,100, filed Sep. 11, 2014. |
U.S. Appl. No. 62/049,128, filed Sep. 11, 2014. |
U.S. Appl. No. 62/104,295, filed Jan. 16, 2015. |
U.S. Appl. No. 62/305,767, filed Mar. 9, 2016. |
Number | Date | Country | |
---|---|---|---|
20180200108 A1 | Jul 2018 | US |
Number | Date | Country | |
---|---|---|---|
62445866 | Jan 2017 | US |